Eli Lilly partnered with Nvidia to construct what the companies say will be the most powerful supercomputer owned and operated by a pharmaceutical firm, aimed at training large AI models for drug discovery and molecular design. The announcement highlights Lilly’s push to accelerate AI‑driven medicinal chemistry, predictive biology, and in silico candidate generation. Nvidia will supply its GPU‑accelerated stack and infrastructure; Lilly plans to use the system for model development across discovery and translational pipelines. Company executives framed the effort as a national competitiveness play for advanced biomedical AI capabilities. Investors and drug developers view the initiative as evidence of big‑pharma commitment to compute‑first discovery; operational details on access, validation, and timelines remain company controlled. For readers: these systems shorten cycles for molecular simulation, protein folding, and generative chemistry—key bottlenecks in modern drug discovery.